05 Sep , 2025 By : Debdeep Gupta
An exchange filing by Glenmark said that it has received approval from the Drugs Controller General of India (DCGI) to commence patient enrollment and dosing in India.
Pharma major Glenmark has started a multi-country Phase 3 clinical trial for Envafolimab, an oncology drug that is currently being used in China for treatment of tumors, the company said in an exchange filing on September 5, sending the shares higher by over 2.5 percent in a weak market.
The drug has a subcutaneous mode of administration, which the company says promises to make immunotherapy more accessible and convenient for patients.
An exchange filing by Glenmark said that it has received approval from the Drugs Controller General of India (DCGI) to commence patient enrollment and dosing in India. The pharma company has already submitted a Clinical Trial Application (CTA) in Russia and is preparing to open additional trial sites in Brazil and Mexico to expand the footprint of the study.
Envafolimab is a novel anti-PD-L1 inhibitor that is administered subcutaneously, and was invented by Alphamab Oncology, co-developed with 3D Medicines Inc since 2016.
0 Comment